Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Glenn J. Bubley, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. U10CA080775 (BUBLEY, GLENN J) May 12, 1999 - Feb 28, 2014
    NIH
    Eastern Cooperative Oncology Group
    Role: Principal Investigator
  2. R03CA070282 (BUBLEY, GLENN J) Sep 1, 1997 - Aug 31, 1999
    NIH
    SEQUENTIAL/ADDITIVE HORMONAL THERAPY FOR PROSTATE CANCER
    Role: Principal Investigator
  3. R29CA051438 (BUBLEY, GLENN J) Apr 1, 1991 - Mar 31, 1996
    NIH
    MECHANISMS OF PLATINUM-INDUCED MUTAGENESIS
    Role: Principal Investigator
  4. K08CA001022 (BUBLEY, GLENN J) Jul 1, 1987 - Jun 30, 1990
    NIH
    NCI CLINICAL INVESTIGATOR AWARD PROGRAM
    Role: Principal Investigator
  5. M01RR001032 (SUKHATME, VIKAS P) Dec 1, 1977 - Mar 31, 2010
    NIH
    General Clinical Research Center
    Role: Co-Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. J Clin Oncol. 2023 Feb 01; 41(4):871-880. PMID: 36256912; PMCID: PMC9901975.
    Citations: 1     Fields:    Translation:Humans
  2. Sperger JM, Emamekhoo H, McKay RR, Stahlfeld CN, Singh A, Chen XE, Kwak L, Gilsdorf CS, Wolfe SK, Wei XX, Silver R, Zhang Z, Morris MJ, Bubley G, Feng FY, Scher HI, Rathkopf D, Dehm SM, Choueiri TK, Halabi S, Armstrong AJ, Wyatt AW, Taplin ME, Zhao SG, Lang JM. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. J Clin Oncol. 2021 09 10; 39(26):2926-2937. PMID: 34197212; PMCID: PMC8425833.
    Citations: 16     Fields:    Translation:HumansCells
  3. D'Amico AV, Xie W, McMahon E, Loffredo M, Medeiros S, Joseph D, Denham J, Kumar P, Bubley G, Sullivan M, Hellwig R, Carlos Vera J, Freter R, Jeffrey Baker W, Wong JY, Renshaw AA, Kantoff PW. Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial. J Clin Oncol. 2021 09 10; 39(26):2938-2947. PMID: 34197181; PMCID: PMC8425842.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  4. Monfared S, Fleishman A, Korets R, Chang P, Wagner A, Bubley G, Kaplan I, Olumi AF, Gershman B. The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance. Urol Oncol. 2021 11; 39(11):783.e21-783.e30. PMID: 33992521.
    Citations: 1     Fields:    Translation:Humans
  5. Shpilsky J, Stevens J, Bubley G. An up-to-date evaluation of abiraterone for the treatment of prostate cancer. Expert Opin Pharmacother. 2021 Jul; 22(10):1227-1234. PMID: 33856289.
    Citations: 1     Fields:    Translation:Humans
  6. McKay RR, Kwak L, Crowdis JP, Sperger JM, Zhao SG, Xie W, Werner L, Lis RT, Zhang Z, Wei XX, Lang JM, Van Allen EM, Bhatt RS, Yu EY, Nelson PS, Bubley GJ, Montgomery RB, Taplin ME. Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. Clin Cancer Res. 2021 07 01; 27(13):3610-3619. PMID: 33849963; PMCID: PMC8254786.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  7. McKay RR, Xie W, Ye H, Fennessy FM, Zhang Z, Lis R, Calagua C, Rathkopf D, Laudone VP, Bubley GJ, Einstein DJ, Chang PK, Wagner AA, Parsons JK, Preston MA, Kilbridge K, Chang SL, Choudhury AD, Pomerantz MM, Trinh QD, Kibel AS, Taplin ME. Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. J Urol. 2021 07; 206(1):80-87. PMID: 33683939; PMCID: PMC9807004.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  8. Kaplan I, Bubley GJ, Bhatt RS, Taplin ME, Dowling S, Mahoney K, Werner E, Nguyen P. Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study. Int J Radiat Oncol Biol Phys. 2021 08 01; 110(5):1416-1422. PMID: 33636278.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  9. McKay RR, Berchuck J, Kwak L, Xie W, Silver R, Bubley GJ, Chang PK, Wagner A, Zhang Z, Kibel AS, Taplin ME. Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials. J Urol. 2021 06; 205(6):1689-1697. PMID: 33502237.
    Citations: 10     Fields:    Translation:Humans
  10. McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL, Sonpavde GP, Kilbridge KL, Choudhury AD, Mortazavi A, Shah AY, Venkatesan AM, Bubley GJ, Siefker-Radtke AO, McKay RR, Choueiri TK. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer. 2021 03 15; 127(6):840-849. PMID: 33216356.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  11. Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP. Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2020 Oct; 52(10):1132. PMID: 32884149.
    Citations: 1     Fields:    
  12. Gjyrezi A, Xie F, Voznesensky O, Khanna P, Calagua C, Bai Y, Kung J, Wu J, Corey E, Montgomery B, Mace S, Gianolio DA, Bubley GJ, Balk SP, Giannakakou P, Bhatt RS. Taxane resistance in prostate cancer is mediated by decreased drug-target engagement. J Clin Invest. 2020 06 01; 130(6):3287-3298. PMID: 32478682; PMCID: PMC7259995.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  13. Schäfer C, Ju Y, Tak Y, Vazquez C, Han SJ, Tan E, Shay JW, Holmqvist M, Danuser G, Schopperle WM, Bubley G. TRA-1-60-positive/CD45low cells found in the peripheral blood of prostate cancer patients with metastatic disease - A proof-of-concept study. Heliyon. 2020 Jan; 6(1):e03263. PMID: 32021935; PMCID: PMC6994489.
    Citations:    
  14. Varkaris A, Bubley G. Enzalutamide in Metastatic Prostate Cancer. N Engl J Med. 2019 10 10; 381(15):1493. PMID: 31597030.
    Citations:    Fields:    Translation:Humans
  15. Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, Wilkinson S, Carrabba NV, Atway R, Shema S, Lake R, Sweet AR, Einstein DJ, Karzai F, Gulley JL, Chang P, Bubley GJ, Balk SP, Ye H, Sowalsky AG. Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. JCO Precis Oncol. 2019; 3. PMID: 31528835.
    Citations: 18     Fields:    
  16. Xu W, Bubley GJ. Repurposed Drugs for Prostate Cancer. Cancer J. 2019 Mar/Apr; 25(2):121-126. PMID: 30896534.
    Citations: 1     Fields:    Translation:Humans
  17. McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, Trinh QD, Chang SL, Harshman LC, Ross AE, Pienta KJ, Lin DW, Ellis WJ, Montgomery B, Chang P, Wagner AA, Bubley GJ, Kibel AS, Taplin ME. Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. J Clin Oncol. 2019 04 10; 37(11):923-931. PMID: 30811282; PMCID: PMC7051849.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  18. Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, Schaefer RJ, Voznesensky OS, Zhang Z, Bubley GJ, Montgomery B, Mostaghel EA, Nelson PS, Taplin ME, Balk SP. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res. 2018 08 15; 78(16):4716-4730. PMID: 29921690; PMCID: PMC6095796.
    Citations: 29     Fields:    Translation:Humans
  19. McKay RR, Montgomery B, Xie W, Zhang Z, Bubley GJ, Lin DW, Preston MA, Trinh QD, Chang P, Wagner AA, Mostaghel EA, Kantoff PW, Nelson PS, Kibel AS, Taplin ME. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis. 2018 09; 21(3):364-372. PMID: 29263420.
    Citations: 18     Fields:    Translation:Humans
  20. Han GC, Hwang J, Wankowicz SAM, Zhang Z, Liu D, Cibulskis C, Gaviola GC, Ghazikhanian V, McKay RR, Bubley GJ, Carter SL, Balk SP, Hahn WC, Taplin ME, Van Allen EM. Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2017; 1. PMID: 32913968; PMCID: PMC7446377.
    Citations: 7     Fields:    
  21. Paller CJ, Zhou XC, Heath EI, Taplin ME, Mayer T, Stein MN, Bubley GJ, Pili R, Hudson T, Kakarla R, Abbas MM, Anders NM, Dowling D, King S, Bruns AB, Wagner WD, Drake CG, Antonarakis ES, Eisenberger MA, Denmeade SR, Rudek MA, Rosner GL, Carducci MA. Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial. Clin Cancer Res. 2018 01 15; 24(2):306-315. PMID: 29113986; PMCID: PMC5771949.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  22. Calagua C, Russo J, Sun Y, Schaefer R, Lis R, Zhang Z, Mahoney K, Bubley GJ, Loda M, Taplin ME, Balk SP, Ye H. Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clin Cancer Res. 2017 Nov 15; 23(22):6812-6822. PMID: 28893901.
    Citations: 49     Fields:    Translation:HumansCells
  23. Zang T, Taplin ME, Tamae D, Xie W, Mesaros C, Zhang Z, Bubley G, Montgomery B, Balk SP, Mostaghel EA, Blair IA, Penning TM. Testicular vs adrenal sources of hydroxy-androgens in prostate cancer. Endocr Relat Cancer. 2017 08; 24(8):393-404. PMID: 28663228; PMCID: PMC5593253.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  24. Bubley GJ, Balk SP. Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide. J Clin Oncol. 2017 07 01; 35(19):2103-2105. PMID: 28414609.
    Citations: 7     Fields:    Translation:HumansCells
  25. Sowalsky AG, Kissick HT, Gerrin SJ, Schaefer RJ, Xia Z, Russo JW, Arredouani MS, Bubley GJ, Sanda MG, Li W, Ye H, Balk SP. Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. Clin Cancer Res. 2017 Jul 15; 23(14):3823-3833. PMID: 28119368; PMCID: PMC5511561.
    Citations: 22     Fields:    Translation:HumansCells
  26. Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin ME. Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res. 2017 May 01; 23(9):2169-2176. PMID: 28151719; PMCID: PMC5570479.
    Citations: 31     Fields:    Translation:Humans
  27. McKay RR, Werner L, Fiorillo M, Roberts J, Heath EI, Bubley GJ, Montgomery RB, Taplin ME. Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2017 08; 15(4):463-471. PMID: 27890446; PMCID: PMC6853188.
    Citations: 4     Fields:    Translation:Humans
  28. McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, Marck BT, Matsumoto AM, Domachevsky L, Zukotynski KA, Bhasin M, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin ME. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2017 Feb 15; 23(4):935-945. PMID: 27683182; PMCID: PMC5315609.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  29. McKay RR, Gray KP, Hayes JH, Bubley GJ, Rosenberg JE, Hussain A, Kantoff PW, Taplin ME. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. Cancer. 2015 Aug 01; 121(15):2603-11. PMID: 25903013; PMCID: PMC4566852.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  30. DiPaola RS, Chen YH, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley JL, Arlen PM, Butterfield LH, Wilding G. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol. 2015 Sep; 68(3):365-71. PMID: 25533418.
    Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
  31. Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015 Mar 15; 21(6):1273-80. PMID: 25320358.
    Citations: 90     Fields:    Translation:HumansCells
  32. Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014 Nov 20; 32(33):3705-15. PMID: 25311217.
    Citations: 99     Fields:    Translation:HumansCTClinical Trials
  33. Sowalsky AG, Xia Z, Wang L, Zhao H, Chen S, Bubley GJ, Balk SP, Li W. Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Mol Cancer Res. 2015 Jan; 13(1):98-106. PMID: 25189356.
    Citations: 48     Fields:    Translation:HumansCells
  34. Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94. PMID: 24821883.
    Citations: 88     Fields:    Translation:HumansCTClinical Trials
  35. Delto JC, Kacker R, Bubley G, DeWolf WC. Intravesical mitomycin therapy for stage T1 and tis high-grade squamous cell carcinoma of the bladder. Clin Genitourin Cancer. 2014 Feb; 12(1):e35-6. PMID: 24169496.
    Citations:    Fields:    Translation:Humans
  36. Rojan A, Funches R, Regan MM, Gulley JL, Bubley GJ. Dramatic and prolonged PSA response after retreatment with a PSA vaccine. Clin Genitourin Cancer. 2013 Sep; 11(3):362-4. PMID: 23791437.
    Citations: 1     Fields:    Translation:Humans
  37. Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2013 Jul; 45(7):747-55. PMID: 23727860; PMCID: PMC3787876.
    Citations: 84     Fields:    Translation:HumansAnimalsCells
  38. Bubley GJ, Bloch BN, Vazquez C, Genega E, Holupka E, Rofsky N, Kaplan I. Accuracy of endorectal magnetic resonance/transrectal ultrasound fusion for detection of prostate cancer during brachytherapy. Urology. 2013 Jun; 81(6):1284-9. PMID: 23490527.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  39. Holupka E, Bubley GJ. Reply: To PMID 23490517. Urology. 2013 Jun; 81(6):1289-90. PMID: 23490531.
    Citations:    Fields:    Translation:Humans
  40. Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, Morganstern DE, Kantoff PW, Taplin ME. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology. 2013 Mar; 81(3):611-6. PMID: 23452809.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  41. Jacobus SJ, Qu AQ, Sweeney C, Appleman LJ, Tretter CP, Bubley GJ, Elfiky A, Park R, Stack EC, Signoretti S, Walsh MK, Steele G, Hirsch MS, Krajewski KM, Taplin ME, Rosenberg JE, Ross RW. A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates. J Clin Oncol. 2013 Feb 20; 31(6_suppl):278. PMID: 28136747.
    Citations:    
  42. Sowalsky AG, Ye H, Bubley GJ, Balk SP. Clonal progression of prostate cancers from Gleason grade 3 to grade 4. Cancer Res. 2013 Feb 01; 73(3):1050-5. PMID: 23204237.
    Citations: 48     Fields:    Translation:Humans
  43. Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012 Dec; 110(11):1729-35. PMID: 22928480.
    Citations: 44     Fields:    Translation:HumansCTClinical Trials
  44. Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F, Gross ME. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin Genitourin Cancer. 2012 Dec; 10(4):232-8. PMID: 22695254; PMCID: PMC3963491.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  45. Klempner SJ, Bubley G. Complementary and alternative medicines in prostate cancer: from bench to bedside? Oncologist. 2012; 17(6):830-7. PMID: 22618569.
    Citations: 13     Fields:    Translation:HumansAnimals
  46. Slater S, Dumas C, Bubley G. Dutasteride for the treatment of prostate-related conditions. Expert Opin Drug Saf. 2012 Mar; 11(2):325-30. PMID: 22316171.
    Citations: 2     Fields:    Translation:HumansAnimals
  47. Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, Hahn NM, Hutson TE, Sonpavde G, Morrissey SC, Buckle GC, Kim WY, Petrylak DP, Ryan CW, Eisenberger MA, Mortazavi A, Bubley GJ, Taplin ME, Rosenberg JE, Kantoff PW. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012 Feb 10; 30(5):507-12. PMID: 22184381; PMCID: PMC4104290.
    Citations: 61     Fields:    Translation:HumansCTClinical Trials
  48. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011 Oct 15; 71(20):6503-13. PMID: 21868758.
    Citations: 215     Fields:    Translation:HumansAnimalsCells
  49. Liu G, Chen YH, Kolesar J, Huang W, Dipaola R, Pins M, Carducci M, Stein M, Bubley GJ, Wilding G. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol. 2013 Feb; 31(2):211-8. PMID: 21784672.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  50. Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, DeWolf WC, Bubley GJ, Funches R, Aronovitz JA, Wei JT, Sanda MG. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol. 2011 Sep; 186(3):865-72. PMID: 21788038; PMCID: PMC3807735.
    Citations: 58     Fields:    Translation:Humans
  51. Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology. 2011 Sep; 78(3):626-30. PMID: 21762967.
    Citations: 35     Fields:    Translation:HumansCTClinical Trials
  52. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61. PMID: 21632851.
    Citations: 93     Fields:    Translation:HumansCTClinical Trials
  53. Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh WV, Morganstern D, Kantoff PW, Regan MM, Taplin M. Follow-up study of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):4657. PMID: 28023914.
    Citations:    
  54. San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol. 2011 Feb; 185(2):471-6. PMID: 21167525.
    Citations: 26     Fields:    Translation:Humans
  55. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 20; 28(9):1496-501. PMID: 20159814.
    Citations: 162     Fields:    Translation:HumansCellsCTClinical Trials
  56. Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7099-105. PMID: 19887483.
    Citations: 34     Fields:    Translation:HumansCTClinical Trials
  57. Joshi MD, Ahmad R, Yin L, Raina D, Rajabi H, Bubley G, Kharbanda S, Kufe D. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther. 2009 Nov; 8(11):3056-65. PMID: 19887552.
    Citations: 47     Fields:    Translation:HumansAnimalsCells
  58. Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA, Sanda MG. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5794-802. PMID: 19737960.
    Citations: 101     Fields:    Translation:HumansAnimalsCells
  59. Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, Sanda MG. Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. Urology. 2009 Nov; 74(5):1156-61. PMID: 19647299.
    Citations: 8     Fields:    Translation:Humans
  60. Ryan C, Efstathiou E, Smith M, Taplin M, Bubley G, Logothetis C, Kheoh T, Haqq C, Molina A, Small EJ. Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol. 2009 May 20; 27(15_suppl):5046. PMID: 27962951.
    Citations:    
  61. Danila DC, de Bono J, Ryan CJ, Denmeade S, Smith M, Taplin M, Bubley G, Molina A, Haqq C, Scher HI. Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto). J Clin Oncol. 2009 May 20; 27(15_suppl):5048. PMID: 27962949.
    Citations:    
  62. Bhatt RS, Bubley GJ. The challenge of herbal therapies for prostate cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7581-2. PMID: 19047081.
    Citations: 2     Fields:    Translation:HumansAnimals
  63. Clement J, Bubley G. Prostasol and venous thromboembolism. Urology. 2008 Sep; 72(3):664-6. PMID: 18602145.
    Citations: 1     Fields:    Translation:Humans
  64. Taplin M, Ko Y, Regan MM, Beer TM, Carducci MA, Mathew P, Bubley G, Oh WK, Kantoff PW, Balk SP. Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). J Clin Oncol. 2008 May 20; 26(15_suppl):5068. PMID: 27948754.
    Citations:    
  65. Chen Y, Wilding G, Gee J, DiPaola RP, Pins M, Carducci MA, Stein MN, Bubley G, Liu G. A phase II trial of lapatinib (GW572016) in patients with recurrent prostate cancer as evident by a rising PSA. J Clin Oncol. 2008 May 20; 26(15_suppl):5170. PMID: 27948236.
    Citations:    
  66. Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 2008 May; 101(9):1084-9. PMID: 18399827.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  67. Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, Bubley GJ. Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU Int. 2008 Aug; 102(3):358-63. PMID: 18394010; PMCID: PMC4112353.
    Citations: 14     Fields:    Translation:HumansCells
  68. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 01; 26(7):1148-59. PMID: 18309951.
    Citations: 883     Fields:    Translation:Humans
  69. Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008 Feb 01; 112(3):521-6. PMID: 18085595.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  70. Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, Ma J. Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate. 2007 Sep 01; 67(12):1354-61. PMID: 17624927.
    Citations: 22     Fields:    Translation:Humans
  71. Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol. 2007 Jun; 177(6):2146-50. PMID: 17509304.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  72. Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2007 Jun; 5(5):323-8. PMID: 17645829.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  73. Masiello D, Mohi MG, McKnight NC, Smith B, Neel BG, Balk SP, Bubley GJ. Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer Biol Ther. 2007 Feb; 6(2):195-201. PMID: 17218776.
    Citations: 11     Fields:    Translation:HumansCells
  74. Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol. 2006 Dec 01; 24(34):5408-13. PMID: 17135641.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  75. Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, Cooper A. Prostate cancer in a transgender woman 41 years after initiation of feminization. JAMA. 2006 Nov 15; 296(19):2316-7. PMID: 17105793.
    Citations: 9     Fields:    Translation:Humans
  76. Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci U S A. 2006 Oct 24; 103(43):15969-74. PMID: 17043241; PMCID: PMC1635111.
    Citations: 101     Fields:    Translation:HumansCells
  77. Torregrossa J, Bubley GJ, Jones GB. Microwave expedited synthesis of 5-aminocamptothecin analogs: Inhibitors of hypoxia inducible factor HIF-1alpha. Bioorg Med Chem Lett. 2006 Dec 01; 16(23):6082-5. PMID: 16971123.
    Citations: 1     Fields:    Translation:HumansCells
  78. Yuan X, Li T, Wang H, Zhang T, Barua M, Borgesi RA, Bubley GJ, Lu ML, Balk SP. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol. 2006 Aug; 169(2):682-96. PMID: 16877366; PMCID: PMC1698802.
    Citations: 38     Fields:    Translation:HumansAnimalsCells
  79. Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol. 2006 Aug; 176(2):520-5. PMID: 16813881.
    Citations: 19     Fields:    Translation:Humans
  80. Miksad RA, Bubley G, Church P, Cooper A, Rofsky N, Kaplan I, Sanda M. Analysis of hormonal receptor status in tissue from prostate cancer that developed 26 years after bilateral orchiectomy and following 41 years of estrogen therapy. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14610. PMID: 27954489.
    Citations:    
  81. Pomerantz M, Manola J, Taplin M, Bubley G, Inman M, Lowell J, Kantoff P, Oh WK. Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):4560. PMID: 27951983.
    Citations:    
  82. Hayes JH, Oh WK, Kantoff PW, Manola JB, Smith MR, Gelmann EP, Bubley G, Balk SP, Taplin M. Mifepristone (RU-486) in androgen independent prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14508. PMID: 27953925.
    Citations:    
  83. Taplin M, Xie W, Morganstern D, Bubley G, Ernstoff M, Regan M. Chemo-hormonal therapy for biochemical progression of prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4559. PMID: 27951992.
    Citations:    
  84. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol. 2006 Jun 20; 24(18):2723-8. PMID: 16782912.
    Citations: 48     Fields:    Translation:Humans
  85. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006 Mar 01; 66(5):2815-25. PMID: 16510604.
    Citations: 470     Fields:    Translation:Humans
  86. Li J, Crasto CF, Weinberg JS, Amiji M, Shenoy D, Sridhar S, Bubley GJ, Jones GB. An approach to heterobifunctional poly(ethyleneglycol) bioconjugates. Bioorg Med Chem Lett. 2005 Dec 15; 15(24):5558-61. PMID: 16236512.
    Citations:    Fields:    Translation:AnimalsCells
  87. Jones GB, Crasto CF, Mathews JE, Xie L, Mitchell MO, El-Shafey A, D'Amico AV, Bubley GJ. An image contrast agent selectively activated by prostate specific antigen. Bioorg Med Chem. 2006 Jan 15; 14(2):418-25. PMID: 16185875.
    Citations: 2     Fields:    Translation:Cells
  88. Yannucci J, Manola J, Garnick M, Bubley G. The effect of androgen deprivation therapy (ADT) on lipid and HbA1C parameters. J Clin Oncol. 2005 Jun; 23(16_suppl):4562. PMID: 27946393.
    Citations:    
  89. Fu XS, Choi E, Bubley GJ, Balk SP. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate. 2005 May 15; 63(3):215-21. PMID: 15538748.
    Citations: 33     Fields:    Translation:HumansCells
  90. Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP. Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer. 2005 Jan 20; 113(3):490-8. PMID: 15455390.
    Citations: 33     Fields:    Translation:HumansCellsCTClinical Trials
  91. Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, Proper J, Weeden W, Miller TE, Chatis P, Egorin MJ, Tahan SR, Dezube BJ. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol. 2005 Feb 10; 23(5):982-9. PMID: 15572730.
    Citations: 49     Fields:    Translation:HumansCellsCTClinical Trials
  92. Ko YJ, Devi GR, London CA, Kayas A, Reddy MT, Iversen PL, Bubley GJ, Balk SP. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. J Urol. 2004 Sep; 172(3):1140-4. PMID: 15311058.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  93. Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol. 2004 Sep 15; 22(18):3705-12. PMID: 15289492.
    Citations: 28     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  94. Randall M, Rini B, Ryan C, Rosenberg J, Garcia J, Bubley G, Small EJ. The addition of imatinib mesylate to estramustine/docetaxel (E/D) for the treatment of hormone refractory prostate cancer (HRPC) patients: Results of a phase I trial. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4617. PMID: 28015756.
    Citations:    
  95. Jones GB, Xie L, El-Shafey A, Crasto CF, Bubley GJ, D'Amico AV. Image contrast agents activated by prostate specific antigen (PSA). Bioorg Med Chem Lett. 2004 Jun 21; 14(12):3081-4. PMID: 15149649.
    Citations: 1     Fields:    
  96. Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T, Gillies SD. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother. 2004 May-Jun; 27(3):232-9. PMID: 15076141.
    Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
  97. George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, Dewolf WC, Kantoff PW, Bubley GJ. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology. 2004 Feb; 63(2):327-32. PMID: 14972483.
    Citations: 7     Fields:    Translation:Humans
  98. Spentzos D, Mantzoros C, Regan MM, Morrissey ME, Duggan S, Flickner-Garvey S, McCormick H, DeWolf W, Balk S, Bubley GJ. Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients. Clin Cancer Res. 2003 Aug 15; 9(9):3282-7. PMID: 12960113.
    Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
  99. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003 Aug; 1(10):707-15. PMID: 12939396.
    Citations: 116     Fields:    Translation:Humans
  100. Bubley G. Models for prostate cancer chemoprevention. Clin Prostate Cancer. 2003 Jun; 2(1):32-3. PMID: 15046681.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  101. Rago RP, Einstein A, Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, Dalton WS. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother Pharmacol. 2003 Apr; 51(4):297-305. PMID: 12721757.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  102. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003 Jan 15; 21(2):383-91. PMID: 12525533.
    Citations: 145     Fields:    Translation:Humans
  103. Zhang PL, Rosen S, Veeramachaneni R, Kao J, DeWolf WC, Bubley G. Association between prostate cancer and serum testosterone levels. Prostate. 2002 Nov 01; 53(3):179-82. PMID: 12386917.
    Citations: 21     Fields:    Translation:Humans
  104. Bubley GJ, Balk SP, Regan MM, Duggan S, Morrissey ME, Dewolf WC, Salgami E, Mantzoros C. Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy. J Urol. 2002 Nov; 168(5):2249-52. PMID: 12394769.
    Citations: 3     Fields:    Translation:Humans
  105. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem. 2002 Jul 19; 277(29):26321-6. PMID: 12015321.
    Citations: 97     Fields:    Translation:HumansAnimalsCells
  106. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol. 2001 Oct 01; 167(7):4046-50. PMID: 11564825.
    Citations: 145     Fields:    Translation:HumansCells
  107. Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci U S A. 2001 Sep 11; 98(19):10823-8. PMID: 11535819; PMCID: PMC58558.
    Citations: 57     Fields:    Translation:AnimalsCells
  108. Ko YJ, Bubley GJ. Prostate cancer in the older man. Oncology (Williston Park). 2001 Sep; 15(9):1113-9, 1123-4; discussion 1124-6, 1131. PMID: 11589062.
    Citations: 3     Fields:    Translation:Humans
  109. Taplin ME, Bubley GJ, Rajeshkumar B, Shuster T, Ko YJ, Morganstern DE. Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer. Semin Oncol. 2001 Aug; 28(4 Suppl 15):32-9. PMID: 11685726.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  110. Bubley GJ. Is the flare phenomenon clinically significant? Urology. 2001 Aug; 58(2 Suppl 1):5-9. PMID: 11502435.
    Citations: 26     Fields:    Translation:Humans
  111. Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, Greenspan SL. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001 Jun; 86(6):2787-91. PMID: 11397888.
    Citations: 43     Fields:    Translation:Humans
  112. Jones GB, Hynd G, Wright JM, Purohit A, Plourde GW, Huber RS, Mathews JE, Li A, Kilgore MW, Bubley GJ, Yancisin M, Brown MA. Target-directed enediynes: designed estramycins. J Org Chem. 2001 Jun 01; 66(11):3688-95. PMID: 11374986.
    Citations: 4     Fields:    Translation:HumansCells
  113. Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJ. A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res. 2001 Apr; 7(4):800-5. PMID: 11309325.
    Citations: 40     Fields:    Translation:HumansCTClinical Trials
  114. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 2000 Dec 06; 92(23):1918-25. PMID: 11106683.
    Citations: 106     Fields:    Translation:HumansCells
  115. Jones GB, Mitchell MO, Weinberg JS, D'Amico AV, Bubley GJ. Towards enzyme activated antiprostatic agents. Bioorg Med Chem Lett. 2000 Sep 04; 10(17):1987-9. PMID: 10987433.
    Citations:    Fields:    Translation:Humans
  116. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 2000 May; 6(5):1632-8. PMID: 10815880.
    Citations: 66     Fields:    Translation:HumansCellsCTClinical Trials
  117. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol. 2000 Feb; 18(4):847-53. PMID: 10673527.
    Citations: 47     Fields:    Translation:Humans
  118. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999 Nov; 17(11):3461-7. PMID: 10550143.
    Citations: 254     Fields:    Translation:Humans
  119. Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M, Mosberger I, Upton MP, Bubley GJ, Balk SP. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol. 1999 Oct; 155(4):1271-9. PMID: 10514409; PMCID: PMC1867033.
    Citations: 50     Fields:    Translation:HumansCells
  120. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999 Jun 01; 59(11):2511-5. PMID: 10363963.
    Citations: 174     Fields:    Translation:Humans
  121. Cenni B, Kim HK, Bubley GJ, Aebi S, Fink D, Teicher BA, Howell SB, Christen RD. Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin. Br J Cancer. 1999 May; 80(5-6):699-704. PMID: 10360646; PMCID: PMC2362265.
    Citations: 4     Fields:    Translation:HumansCells
  122. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol. 1998 Jan; 159(1):149-53. PMID: 9400459.
    Citations: 34     Fields:    Translation:Humans
  123. Sun Z, Pan J, Bubley G, Balk SP. Frequent abnormalities of TSG101 transcripts in human prostate cancer. Oncogene. 1997 Dec 18; 15(25):3121-5. PMID: 9444960.
    Citations: 17     Fields:    Translation:HumansCells
  124. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res. 1997 Aug; 3(8):1383-8. PMID: 9815822.
    Citations: 66     Fields:    Translation:AnimalsCells
  125. Kibel AS, Downs TM, Bubley GJ, DeWolf WC. Squamous cell carcinoma of the renal pelvis with inferior vena caval extension. J Urol. 1996 Oct; 156(4):1436. PMID: 8808892.
    Citations: 3     Fields:    Translation:HumansCells
  126. Xu J, Bubley GJ, Detrick B, Blankenship LJ, Patierno SR. Chromium(VI) treatment of normal human lung cells results in guanine-specific DNA polymerase arrest, DNA-DNA cross-links and S-phase blockade of cell cycle. Carcinogenesis. 1996 Jul; 17(7):1511-7. PMID: 8706257.
    Citations: 24     Fields:    Translation:HumansCells
  127. Bubley GJ, Balk SP. Treatment of metastatic prostate cancer. Lessons from the androgen receptor. Hematol Oncol Clin North Am. 1996 Jun; 10(3):713-25. PMID: 8773507.
    Citations: 3     Fields:    Translation:Humans
  128. Bubley GJ, Xu J, Kupiec N, Sanders D, Foss F, O'Brien M, Emi Y, Teicher BA, Patierno SR. Effect of DNA conformation on cisplatin adduct formation. Biochem Pharmacol. 1996 Mar 08; 51(5):717-21. PMID: 8615910.
    Citations: 8     Fields:    Translation:HumansCells
  129. Bubley GJ, Balk SP. Treatment of Androgen-Independent Prostate Cancer. Oncologist. 1996; 1(1 & 2):30-35. PMID: 10387966.
    Citations: 5     Fields:    
  130. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995 May 25; 332(21):1393-8. PMID: 7723794.
    Citations: 324     Fields:    Translation:HumansCells
  131. Bubley GJ, Ogata GK, Dupuis NP, Teicher BA. Detection of sequence-specific antitumor alkylating agent DNA damage from cells treated in culture and from a patient. Cancer Res. 1994 Dec 15; 54(24):6325-9. PMID: 7987822.
    Citations: 1     Fields:    Translation:HumansCells
  132. Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W, et al. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol. 1994 Dec; 12(12):2634-9. PMID: 7527455.
    Citations: 26     Fields:    Translation:HumansCells
  133. Bubley GJ, Teicher BA, Ogata GK, Sandoval LS, Kusumoto T. Differences in in vivo and in vitro sequence-specific sites of cisplatin-DNA adduct formation and detection of a dose-response relationship. Biochem Pharmacol. 1994 Jul 05; 48(1):145-53. PMID: 8043016.
    Citations: 1     Fields:    Translation:HumansCells
  134. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994 May 15; 83(10):2759-79. PMID: 8180373.
    Citations: 176     Fields:    Translation:Humans
  135. Bubley GJ, Ashburner BP, Balk SP, Ara G, Varshaney A, Teicher BA. Identification of cis-diamminedichloroplatinum(II) adducts in DNA from drug-treated human cell nuclei. Biotechniques. 1992 May; 12(5):694, 696, 698. PMID: 1515136.
    Citations:    Fields:    Translation:HumansCells
  136. Teicher BA, Herman TS, Tanaka J, Eder JP, Holden SA, Bubley G, Coleman CN, Frei E. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. Cancer Res. 1991 Feb 15; 51(4):1086-91. PMID: 1825474.
    Citations: 5     Fields:    Translation:Animals
  137. Teicher BA, Herman TS, Shulman L, Bubley G, Coleman CN, Frei E. Combination of etanidazole with cyclophosphamide and platinum complexes. Cancer Chemother Pharmacol. 1991; 28(3):153-8. PMID: 1830248.
    Citations: 4     Fields:    Translation:AnimalsCells
  138. Bubley GJ, Ashburner BP, Teicher BA. Spectrum of cis-diamminedichloroplatinum(II)-induced mutations in a shuttle vector propagated in human cells. Mol Carcinog. 1991; 4(5):397-406. PMID: 1910483.
    Citations: 9     Fields:    Translation:HumansCells
  139. Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol. 1990 Apr; 8(4):648-56. PMID: 2313334.
    Citations: 12     Fields:    Translation:Humans
  140. Schnipper LE, Bubley GJ. Viral infections and cancer. Compr Ther. 1990 Mar; 16(3):42-8. PMID: 2156656.
    Citations:    Fields:    Translation:HumansCells
  141. Chambers LA, Leonard SS, Whatmough AE, Weller PF, Bubley GJ, Kruskall MS. Management of hypereosinophilic syndrome with chronic plasma- and leukapheresis. Prog Clin Biol Res. 1990; 337:83-5. PMID: 2353022.
    Citations:    Fields:    Translation:Humans
  142. Rukstalis DB, Bubley GJ, Donahue JP, Richie JP, Seidman JG, DeWolf WC. Regional loss of chromosome 6 in two urological malignancies. Cancer Res. 1989 Sep 15; 49(18):5087-90. PMID: 2766279.
    Citations: 5     Fields:    Translation:HumansCells
  143. Bubley GJ, Chapman B, Chapman SK, Crumpacker CS, Schnipper LE. Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions. Antimicrob Agents Chemother. 1989 Jun; 33(6):862-5. PMID: 2669626.
    Citations: 10     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  144. Bubley GJ, Balzarini J, Crumpacker CS, de Clercq E, Schnipper LE. The effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on DNA repair and mutagenesis of herpes simplex virus type 1. Virology. 1987 Nov; 161(1):242-4. PMID: 2823464.
    Citations: 1     Fields:    Translation:AnimalsCells
  145. Crumpacker C, Heagy W, Bubley G, Monroe JE, Finberg R, Hussey S, Schnipper L, Lucey D, Lee TH, McLane MF, et al. Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). A phase 1 study shows transient clinical improvement associated with suppression of the human immunodeficiency virus and enhanced lymphocyte proliferation. Ann Intern Med. 1987 Nov; 107(5):664-74. PMID: 3662279.
    Citations: 9     Fields:    Translation:HumansCells
  146. Bubley GJ, Schnipper LE. Effects of Bloom's syndrome fibroblasts on genetic recombination and mutagenesis of herpes simplex virus type 1. Somat Cell Mol Genet. 1987 Mar; 13(2):111-7. PMID: 3031825.
    Citations: 6     Fields:    Translation:HumansCells
  147. Crumpacker C, Bubley G, Lucey D, Hussey S, Connor J. Ribavirin enters cerebrospinal fluid. Lancet. 1986 Jul 05; 2(8497):45-6. PMID: 2873344.
    Citations: 14     Fields:    Translation:Humans
  148. Bubley GJ, Crumpacker CS, Schnipper LE. Incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and mutagenesis of herpes simplex virus type 1. Antimicrob Agents Chemother. 1986 Apr; 29(4):716-9. PMID: 3010854.
    Citations:    Fields:    Translation:Cells
  149. Oliver S, Bubley G, Crumpacker C. Inhibition of HSV-transformed murine cells by nucleoside analogs, 2'-NDG and 2'-nor-cGMP: mechanisms of inhibition and reversal by exogenous nucleosides. Virology. 1985 Aug; 145(1):84-93. PMID: 2990104.
    Citations: 9     Fields:    Translation:AnimalsCells
  150. Bubley GJ, Crumpacker CS, Schnipper LE. Repair of DNA following incorporation of 1-beta-D-arabinofuranosylcytosine into herpes simplex virus type 1. Cancer Res. 1984 May; 44(5):1813-8. PMID: 6324990.
    Citations: 1     Fields:    Translation:AnimalsCells
  151. Bubley G, Crumpacker C, De Clercq E, Schnipper L. Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on the proliferation of herpes simplex virus type 1-transformed and thymidine kinase-deficient mouse cells. Virology. 1983 Sep; 129(2):490-2. PMID: 6312685.
    Citations:    Fields:    Translation:AnimalsCells
  152. Bubley G, Come P, MacDougall D, Thurer R, Goldberg J. Pericardial tamponade associated with myeloid metaplasia. Am J Hematol. 1983 Apr; 14(2):185-8. PMID: 6837572.
    Citations: 2     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Bubley's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (586)
Explore
_
Co-Authors (75)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.